FDG-pet in paraneoplastic syndromes

Area of Science:

• Oncology
• Nuclear Medicine
• Radiology

Background:

• Paraneoplastic syndromes are rare but clinically significant disorders.
• Their manifestations can precede the underlying malignancy by years, complicating diagnosis.
• Prompt identification and treatment of the associated tumor are essential.

Purpose of the Study:

• To highlight the importance of early diagnosis in managing paraneoplastic syndromes.
• To evaluate the utility of combined FDG-PET and CT in identifying associated malignancies.
• To assess the role of FDG-PET in diagnosing and monitoring paraneoplastic neurological disorders.

Main Methods:

• Review of diagnostic approaches for paraneoplastic syndromes.
• Evaluation of fluorodeoxyglucose-positron emission tomography (FDG-PET) combined with computed tomography (CT) for tumor detection.
• Assessment of cerebral FDG-PET for diagnosing paraneoplastic encephalitis.

Main Results:

• Combined FDG-PET/CT demonstrates high sensitivity for detecting primary tumors or recurrences.
• This imaging modality effectively differentiates malignant lesions from benign or inflammatory findings.
• Cerebral FDG-PET aids in confirming paraneoplastic encephalitis and monitoring treatment response.

Conclusions:

• Early diagnosis of paraneoplastic syndromes is critical, as tumor therapy remains the primary treatment.
• Combined FDG-PET/CT is a valuable tool for sensitive tumor localization and characterization.
• FDG-PET plays a role in diagnosing and managing specific neurological paraneoplastic syndromes.